EU needs to modify existing guidance for nanotech risk assessment
This article was originally published in Clinica
Executive Summary
Modifications to the existing EU technical guidance for the risk assessment of chemicals will be necessary for nanomaterials, including those used in medical technology. That is the view of the EU's Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR), which has just published a scientific opinion on the appropriateness of the EU Technical Guidance Documents for chemicals in regard to nanomaterials.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.